Morepen Strengthens Integrated CDMO Capabilities with First U.S. ANDA Submission for Sitagliptin Tablets
Morepen Laboratories files its first US ANDA for Sitagliptin tablets, marking a major expansion into integrated CDMO and finished dosage development.
Morepen Laboratories Limited has reached a significant milestone in its expansion strategy by submitting its first Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration (FDA). This filing is for Sitagliptin Tablets USP, available in 25 mg, 50 mg, and 100 mg strengths.
This strategic move signals the company's evolution from an established Active Pharmaceutical Ingredient (API) manufacturer into a comprehensive Contract Development and Manufacturing Organization (CDMO) capable of handling integrated finished dosage development and complex regulatory filings.
Expanding Integrated CDMO Capabilities
The Sitagliptin program represents a massive technical undertaking for Morepen, integrating several high-level pharmaceutical processes. The company's internal capabilities were utilized across the entire development lifecycle, including:
- Formulation and Scale-up: Transitioning from lab-scale to manufacturing-scale production.
- Analytical Excellence: Development and validation of analytical methods and rigorous impurity control.
- Stability and Compliance: Conducting stability studies and manufacturing regulatory batches under strict GMP systems.
- Regulatory Strategy: Coordinating bioequivalence strategies, working with contract research organizations, and compiling complex regulatory dossiers.
By mastering this end-to-end process, Morepen is now positioned to undertake more specialized and complex CDMO assignments, offering a seamless transition from API development to finished dosage formulation and final regulatory submission.
A Strategic Step for Future Growth
Mr. Sanjay Suri, Managing Director of Morepen Laboratories Limited, emphasized that capability building is the cornerstone of the company's next growth phase. He noted that this first ANDA submission successfully merges scientific, manufacturing, and regulatory expertise required to move an API through to a formal U.S. filing.
Looking ahead, Morepen aims to leverage this momentum through:
- Innovation Hubs: Investing in advanced chemistry and new technologies.
- Global Expansion: Using these capabilities to support product development in regulated markets across Europe and Asia.
- Advanced Pathways: Exploring differentiated formulations and potential U.S. 505(b)(2) development programs.
- Strategic Partnerships: Building long-term development, technology transfer, and licensing opportunities with global pharmaceutical players.
The Sitagliptin Market Context
Sitagliptin is a widely used oral treatment for adults living with Type 2 diabetes. It belongs to the DPP-4 inhibitor class, often referred to as "gliptins." The market potential for this molecule is substantial; for instance, the innovator product, Januvia, reported worldwide sales of approximately USD 1.604 billion in 2025.
The regulatory landscape for Sitagliptin is shifting. The relevant U.S. phosphate salt patent is slated to expire on November 24, 2026, with pediatric exclusivity extending until May 2027. While some manufacturers may enter the market earlier through separate arrangements, Morepen currently estimates a timeline of 24 to 36 months from the date of submission to progress toward approval and commercial supply, depending on FDA review and facility inspections.
Note: The ANDA submission does not guarantee FDA acceptance, substantive review, or product approval for U.S. commercial supply.